March 1, 2017 / 1:45 PM / 6 months ago

BRIEF-Sangamo Therapeutics receives orphan drug designation from the FDA for SB-913 genome editing treatment for MPS II

March 1 (Reuters) - Sangamo Therapeutics Inc:

* Sangamo Therapeutics receives orphan drug designation from the fda for sb-913 genome editing treatment for mps ii

* Sangamo therapeutics inc - in 2017, sangamo is conducting phase 1/2 clinical trial evaluating sb-913 as an in vivo genome editing treatment for mps ii

* Sangamo Therapeutics Inc - sangamo has also submitted an application to FDA for rare pediatric disease designation for sb-913

* Sangamo Therapeutics- data from studies,from clinical trial for fourth lead program, sb-525, a gene therapy approach for hemophilia a, are expected in late 2017 or early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below